Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Tim A. Kanters's publication output changed over time?
ScholarIQpublication output · 2011–2023
Output grew0% over the shown period — from 1 works in 2011 to 1 in 2023.
1
1
1
1
2
2
1
1
1
201120132014201520172018202020212023
What are the most-cited papers on Tim A. Kanters?
ScholarIQmost cited works
Update of the Dutch manual for costing studies in health care
Tim A. Kanters, Clazien Bouwmans, Naomi van der Linden, Siok Swan Tan, Leona Hakkaart‐van Roijen
PLoS ONE. 2017280 CitationsOPEN ACCESS
Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow‐up
Deniz Güngör, Michelle E. Kruijshaar, Iris Plug, Dimitris Rizopoulos, Tim A. Kanters, Stephan C.A. Wens, Arnold Reuser, Pieter A. van Doorn, Ans T. van der Ploeg
S186577254. 201570 CitationsOPEN ACCESS
Burden of illness of Pompe disease in patients only receiving supportive care
Tim A. Kanters, M.L.C. Hagemans, Nadine A. M. E. van der Beek, Frans Rutten, Ans T. van der Ploeg, Leona Hakkaart
S186577254. 201138 CitationsOPEN ACCESS
Potential cost savings owing to the route of administration of oncology drugs
M Franken, Tim A. Kanters, Jules L.L.M. Coenen, Paul de Jong, Harry R. Koene, Pieternella J. Lugtenburg, Agnes Jager, Carin A. Uyl‐de Groot
S158028025. 201836 CitationsOPEN ACCESS
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
Tim A. Kanters, Iris Hoogenboom-Plug, Maureen Rutten‐van Mölken, Ken Redekop, Ans T. van der Ploeg, Leona Hakkaart
Orphanet Journal of Rare Diseases. 201434 CitationsOPEN ACCESS
Related on ScholarIQ
Erasmus University Rotterdam
Institution
Update of the Dutch manual for costing studies in health care
Paper
Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow‐up
Paper
Burden of illness of Pompe disease in patients only receiving supportive care
Paper
Potential cost savings owing to the route of administration of oncology drugs
Paper
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
Paper